Insulin absorption in lipohypertrophy is poor
A new study has confirmed people with type 1 diabetes do not absorb insulin effectively when injecting into lipohypertrophy (LH). The Glucose Clamp study, was conducted by Famulla et al, which ...
A new study has confirmed people with type 1 diabetes do not absorb insulin effectively when injecting into lipohypertrophy (LH). The Glucose Clamp study, was conducted by Famulla et al, which ...
Type 2 diabetes could be slashed by 80 per cent if more was done to encourage people with “pre-diabetes” diagnoses to change their lifestyles, according to new research. A team from ...
A risk score to identify people who are likely to develop type 2 diabetes has been translated into two further languages. The part NIHR-funded Leicester Risk Score – which is recommended by ...
A total of £40m has been pledged to support a wider programme of investment in helping treat and care for people who already have diabetes. The plans were unveiled in the 2017-2019 NHS ...
Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has ...
The glucagonlike-peptide 2 (GLP-1) agonist liraglutide (Victoza) delays the progression of renal events, according to new research. The findings, carried out by Novo Nordisk, found particularly ...
The next generation of diabetes leaders learned a new range of invaluable skills at a leadership programme staged at the Leicester Diabetes Centre (LDC). More than 20 diabetes specialist nurses ...
A link between pre-eclampsia in pregnancy and the development of diabetes in later life has been found in a new study. The condition, which results in high blood pressure and protein in the ...
A video resource website aimed to help young people and their families manage their type 1 diabetes better has been launched. DigiBete has been created in partnership with the diabetes team at ...
The combination of a GLP-1 receptor agonist and an SGLT-2 inhibitor has shown positive results in those with type 2 diabetes who do not respond to metformin. The DURATION-8 trial showed Bydureon® ...